NEW YORK – Mammoth Biosciences said on Thursday that it has signed agreements with MilliporeSigma and Hamilton Company to commercialize a high-throughput, CRISPR-based SARS CoV-2 test.
NEW YORK – Mammoth Biosciences said on Thursday that it has signed agreements with MilliporeSigma and Hamilton Company to commercialize a high-throughput, CRISPR-based SARS CoV-2 test.
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.